Erectile dysfunction following retropubic prostatectomy by Lalong-Muh, J. et al.
Lalong-Muh, J., Treacy, C. & Steggall, M.J. (2013). Erectile dysfunction following retropubic 
prostatectomy. British Journal of Nursing, 22(4), S4-S9. doi: 10.12968/bjon.2013.22.Sup2.S4 
City Research Online
Original citation: Lalong-Muh, J., Treacy, C. & Steggall, M.J. (2013). Erectile dysfunction following 
retropubic prostatectomy. British Journal of Nursing, 22(4), S4-S9. doi: 
10.12968/bjon.2013.22.Sup2.S4 
Permanent City Research Online URL: http://openaccess.city.ac.uk/7175/
 
Copyright & reuse
City University London has developed City Research Online so that its users may access the 
research outputs of City University London's staff. Copyright © and Moral Rights for this paper are 
retained by the individual author(s) and/ or other copyright holders.  All material in City Research 
Online is checked for eligibility for copyright before being made available in the live archive. URLs 
from City Research Online may be freely distributed and linked to from other web pages. 
Versions of research
The version in City Research Online may differ from the final published version. Users are advised 
to check the Permanent City Research Online URL above for the status of the paper.
Enquiries
If you have any enquiries about any aspect of City Research Online, or if you wish to make contact 
with the author(s) of this paper, please email the team at publications@city.ac.uk.
1 
 
Prevalence and treatment options for erectile dysfunction following retropubic 
prostatectomy for prostate cancer. 
Abstract 
Prostate cancer is the most common cancer affecting men in the UK. Treatment options for 
prostate ĐaŶĐer depeŶd oŶ the grade of tuŵour, the patieŶt͛s Đo-existing diseases, and 
patient choice of treatment. One potentially curative option is surgery, specifically a radical 
retropubic prostatectomy or variation thereof. As a consequence of the surgery, men 
commonly experience two side effects, urinary incontinence and erectile dysfunction (ED). 
This paper outlines the clinical management of ED following surgery and aims to provide an 
overview of how to assess a man who has developed ED and discuss the various treatment 
options available, along with the efficacy in terms of recovery of erections.  
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Introduction  
Prostate cancer is the most common cancer in men, accounting for approximately 23% of all 
new diagnoses and around 13% of deaths, or around 35,000 new diagnoses each year with 
10,000 deaths in England and Wales (Bolland, 2008). Early stage prostate cancer is 
essentially a symptomless disease, particularly if the tumour is localised to the prostate, and 
tends to be found during digital rectal examination and/or via a blood sample (prostate 
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specific antigen or PSA). If the rectal examination is abnormal (i.e. a hard or woody feeling 
prostate is felt) and/or the PSA level is above the age-adjusted norm, the patient is referred 
to the Urology team for further investigation (usually biopsy and computerised tomography 
or bone scan to determine if the tumour has spread).  
 
For organ-confined prostate cancer, treatment options include watchful waiting, active 
surveillance (where patients are not given active treatment but are reviewed every 6 
months radical retropubic prostatectomy (RRP); robotic assisted, radical radiotherapy; 
brachytherapy; and hormone treatment. A radical prostatectomy has the potential to 
completely remove the tumour although the common side effects include erectile 
dysfunction (ED) (20-80%) and urinary incontinence (4-21%) (Bolland, 2008). The cause of 
these side effects is related to the damage to the neurovascular bundles that lie close to the 
prostate. Although surgeons attempt to preserve the neurovascular bundles with nerve-
sparing surgery, ED is a common side effect, as is penile shortening and urinary 
incontinence. Even with nerve-sparing surgery, there is a temporary period of neuropraxia 
where the patient has no spontaneous erections and this can predispose him to penile 
hypoxia, resulting in permanent damage to the structures in the penis (Raina, 2007). It is 
difficult to predict the length of time that neuropraxia can last, with some researchers 
suggesting it is between 9 and 24 months (Zippe, et al. 2001). A goal of ED management is 
therefore to restore blood flow (and oxygenation) to the penis at an early stage and prevent 
neuropraxia. This paper examines how to assess a man who has developed ED and explains 
what treatment options are available to help a) prevent neuropraxia, b) recover erections, 
and c) limit penile shortening. 
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Erectile dysfunction 
Erectile dysfunction (ED) is the inability to maintain an erection sufficient for adequate 
sexual intercourse (NIH Consensus, 1993).   Following radical prostatectomy Korfage, et al. 
(2005) reported an 88% increase in the prevalence of ED, which can have a major effect on 
the iŶdiǀidual͛s self-esteem, quality of life, confidence and life satisfaction resulting in 
depression and fear (Kubin, et al. 2003). 
 
Assessment of ED 
A critical question is when to introduce the discussion to patients, i.e. whether pre-surgery 
or post-surgery. Since ED is a known and common side effect of prostatectomy, patients 
ideally need to be seen by the ED team before surgery, after the multi-disciplinary panel and 
the patient have agreed on the most suitable treatment for the cancer. 
Taking a comprehensive history (refer to Box 1) enables accurate treatment of ED to be 
offered. Although the cause of ED is most likely to be the radical prostatectomy, it is also 
necessary to determine if the patient is hypertensive, diabetic, has vascular disease, renal 
disease or hypogonadism (Steggall, 2011). Ideally the assessment should involve the 
patieŶt͛s seǆual partŶer although this is not always possible.  
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Assessment  Rationale  Implication for treatment 
Surgical history  Nerve-sparing or non-nerve 
sparing surgery? 
An earlier recovery of erectile 
function may be possible men 
who have had nerve-sparing 
surgery 
Medical history Co-existing disease, e.g. diabetes 
mellitus, cardiac disease? 
Continence difficulty following 
surgery? 
Pre-existing ED will mean 
recovery of sexual function 
may be more difficult/take 
more time. Severe ED pre-
surgery will make recovery of 
erections extremely difficult. If 
incontinent, treatment may be 
delayed until continence 
resolved 
Current medication  Anti-hypertensive use can make 
management of ED more difficult 
Check for contra-indications to 
pharmacological treatment for 
ED 
Allergies  Interaction with treatment Interaction with treatment 
Tobacco  On-going tobacco use worsens 
vascular damage 
Smoking cessation is strongly 
recommended 
Alcohol (or illicit 
drugs);  
Desensitises the individual to 
stimulation 
Potential to effect success of 
treatment 
Specific history    
Description of the 
problem  
Erection failure/loss of desire? 
Duration of problem? 
ED is an expected consequence 
of radical prostate surgery but 
patients need to remain 
intimate with their partner  
Early morning 
tumescence (EMT)?  
A small cohort of men will 
maintain EMT 
Indicates that recovery of 
erections may be early  
Libido  Assess desire for on-going sexual 
activity 
Men may prefer to delay 
treatment (to recover from 
surgery) although penile 
rehabilitation should ideally 
ďegiŶ arouŶd ϲ ǁeeks͛ after 
surgery (after removal of a 
urinary catheter) 
Is penetration 
possible?  
Assess strength of erection Assesses blood flow; may 
iŶdiĐate ͚streŶgth͛ of 
medication required. Is the 
erection better during 
masturbation? If yes, there 
may be a relationship issue to 
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be explored 
Is intimacy still 
present?  
Need to know if there is some 
sexual activity 
Absence of intimacy is 
important for both physical 
and mental health 
Psychological factors.  
Social problems 
(particularly prior to 
onset of problem) 
Anxieties inhibit function 
 
 
 
FeeliŶgs of ͚iŵpoteŶĐe͛ iŶ 
other areas will be reflected in 
sexuality – need to resolve 
underlying problem. 
Does the partner 
know of their visit? 
Status of relationship Address unresolved issues with 
both partners 
Box 1 Assessment of ED in men following radical prostatectomy 
 
International index of erectile function (IIEF) 
One way of establishing the severity of ED is by using the International Index of Erectile 
Function or IIEF, which is either a 5- or 15-iteŵ that ͚sĐores͛ ereĐtioŶ diffiĐultǇ ;‘oseŶ, et al. 
1997). The 5-item inventory (also referred to as the Sexual Health Inventory Male or SHIM) 
has good reliability and validity, and has been used extensively in studies of ED (Mahmood 
et al, 2012). It classifies ED severity with the breakpoint scores of: 1–7 = severe ED; 8–11 = 
moderate ED; 12–16 = mild to moderate ED; and 17–21 = mild ED. Scores > 21 indicated 
͚Ŷorŵal͛ seǆual fuŶĐtioŶ ;Cappelleri aŶd ‘oseŶ, 200ϱͿ. Following surgery, SHIM scores tend 
to fall from a baseline of around 22 (no ED) to around 4 (Severe ED) (Raina, et al. 2006), 
irrespective of whether the surgery was nerve sparing or non-nerve sparing). 
 
 
 
6 
 
When is sexual activity advisable following radical retropubic prostatectomy?  
Provided there are no surgical complications treatment for ED can begin around 6 weeks 
after surgery. If incontinent of urine, resumption of sexual activity may be delayed, but this 
should not prevent some form of treatment for ED as the goal is to prevent or limit 
neuropraxia. However, patients should refrain from attempting sexual activity if they have 
any unstable cardiac condition or have had any cardiac event within the last 3 months. 
There is an energy requirement for sexual activity of 3.7 to 5 metabolic equivalents (METs) 
(Sainz, et al. 2004) which equates to climbing 2 flights of stairs without getting very short of 
breath/use a lawn mower to cut a small lawn. If the patient cannot undertake those 
activities they should not be considered fit enough to attempt sexual activity (Steggall and 
Butler, 2012).  
 
Treatment options 
The aim of treatment for erectile dysfunction is to restore sexual function, although it is not 
necessarily penetration/maintenance of an erection that is of critical importance, but the 
intimacy that sexual activity brings. A man who has undergone RRP will have to come to 
terms with the initial cancer diagnosis as well as the changes to his body that the surgery 
brings, and his partner will have also had to rationalise the journey that they have been 
through.  Sexual activity is primarily concerned with communication as well as sexual 
intercourse; in a relationship where avoidance of intimacy has occurred, the first step 
should be a discussion with the sexual partner of what each person expects from the 
encounter and what will need to be done to aid return of erections.  
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There are a range of options for managing ED in men who have had RRP and these include 
tablets, phosphodiesterase type 5 inhibitors (PDE5Is), Medicated Urethral System for 
Erections (MUSE), intracavernosal injections, vacuum devices, counselling and penile 
prosthesis (Steggall, 2011). There is Ŷo forŵal ͚first-liŶe͛ therapǇ aŶd the deĐisioŶ regarding 
which option to choose is based on patient preference, tolerability and likely efficacy (refer 
to table 2).  
Name  Dosage Administration 
guidance 
Contraindications  
Sildenafil Citrate 25, 50 or 100mg 
as required 
Takes an hour to 
work; taken on 
an empty 
stomach; 
Where sexual 
activity is 
inadvisable; 
concomitant use of 
nitrates; caution 
with alpha blockers 
(recommend 
reduced dose); use 
with Nicorandil;  
 
Tadalafil 2.5 or 5mg once 
a day; 10-20mg 
as required 
Daily dosing 
takes 5-7 days to 
reach steady-
state plasma 
concentrations;  
PRN – takes 
between 30 
minutes and 2 
hours to work; 
can be taken 
with food and 
alcohol; 
As above 
Vardenafil 10-20mg as 
required 
Takes around 30 
minutes to work; 
can be taken 
with food and 
As above 
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alcohol 
Medicated Urethral 
System for Erections 
(MUSE) 
125-1000µg as 
required 
Need to pass 
urine 
beforehand; 
takes 15 minutes 
to be absorbed 
Both MUSE and ICI 
can also 
lower blood 
pressure, and 
therefore baseline 
blood 
pressure levels are 
needed before 
administration. Test 
doses of MUSE and 
ICI should be given 
in secondary 
care in case of 
anaphylaxis or other 
adverse event 
Intracavernosal 
injections 
(Viridal/Caverject) 
2.5-40µg as 
required 
Takes around 15 
minutes to work; 
As above, but 
additionally:  
bleeding from 
the injection site, 
needle phobia, 
scarring, increased 
risk of acquiring 
sexually transmitted 
infections and 
priapism (an 
erection that lasts 
for several hours) 
(Urciuoli et al., 
2004).  
 
Vacuum (erection) 
devices 
Used daily as a 
training aid; 
with a 
constriction 
band for sexual 
activity 
Takes between 
10-30 minutes to 
get an erection;  
Should be avoided in 
men with a pre-
disposition to 
bruising;  
Table 2 Treatment options for managing erectile dysfunction following RRP 
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The role of the nurse 
A key role for the nurse is to identify the risks for developing ED, and to have a strategy or 
pathway to begin discussions of ED treatment options, preferably before the patient has 
surgery. Once the patient is having treatment, the plan is then one of guidance and 
encouragement until the man has restored his sexual function.  
 
Phosphodiesterase type 5 inhibitors (PDE5Is) 
There are a number of studies that have used PDE5Is in men who have had RRP that utilised 
the IIEF to deterŵiŶe ͚suĐĐesses or ͚failure͛ Zagaja, et al. (2000) contended that daily use 
Sildenafil resulted in improved quality erection, although the results were more marked in 
men who were younger and previously potent, and had nerve-sparing surgery. These results 
were echoed in Padma-Nathan, et al. (2008) although they used sildenafil citrate each night, 
and concluded that administration of 50 or 100mg for 36 weeks increased return of 
spontaneous erections. Although Gontero, et al. (2005) identified that up to 10% of men 
using sildenafil citrate improved the quality of their erection, 50% of men had ceased to use 
any form of intervention within 1 year of surgery. Furthermore, Chen, et al. (2001) using 
sildenafil citrate identified that 79% reported adverse reactions to the medication such as 
flushing, headache, dizziness and eye redness, which may contribute to discontinuation long 
term. From the literature available, it can be concluded that PDE5Is may improve erection 
recovery (Montorsi and McCullough, 2005) although it remains to be seen whether men 
remain on therapy long term. 
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Alprostadil 
Intracavernosal injections (ICI) have been used in the clinical management of ED although 
the need for motivation is high as the man needs to give himself and injection into his penis 
on each occasion that sexual activity is desired. Yiou, et al. (2010) concluded that, whilst ICI 
improved tumescence post-surgery, the quality of the erection was not as firm as pre-
operative levels, and there was a high drop out from treatment due to the side effect of 
painful erections. Raina, et al. (2007) used Medicated Urethral System for Erection (MUSE) 
three times per week for 6 months, and reported that this resulted in a shortened time to 
erectile recovery; half of their sample were able to have successful penetration after 6 
months of treatment although all reported side effects of urethral burning/penile pain. 
 
Non-pharmacological interventions 
The studies that have used vacuum devices have found an overall improvement in IIEF and 
satisfaction with erections at various time points following surgery, as well as preventing 
penile atrophy (Yuan, et al. 2010). Raina, et al. (2006) who used daily use vacuum therapy 1-
month post-surgery identified that IIEF increased in the treatment group and that those 
who regularly used the vacuum device had markedly less penile shortening. Kohler, et al. 
(2007) conducted a similar study although they used a longer time frame for active 
treatment (12-months) and also identified an increase in IIEF and reduction in penile 
shortening.  
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Combination approaches 
Chen, et al. (2001) compared preference between vacuum therapy and sildenafil citrate and 
although preference was for oral medication, efficacy (in terms of improved IIEF) was 
greater in men using a vacuum device. Raina, et al. (2010) compared vacuum therapy with 
sildenafil citrate, identifying that both sexual satisfaction and penile rigidity was improved 
with a combination approach compared with single therapy alone. Mydlo, et al. (2005) 
examined Sildenafil Citrate or Vardenafil titrated to maximum doses followed by ICI, 
concluding that a combination approach facilitated improvements in sexual satisfaction and 
erection recovery.  
From the corpus of literature available, it would seem that vacuum devices have a role in 
both recovery of erections, reducing neuropraxia and in preventing penile shortening 
(Dalkin, et al. 2007) provided they are used regularly (every day or two) over a 3- 6-month 
period, although could be longer, particularly in men who had erection trouble before 
surgery. However, not all men will benefit from (or want) combination approaches and may 
wish to consider a penile prosthesis. 
 
Penile prosthesis 
If pharmacological or vacuum therapy is unsuccessful, or if the patient prefers, he can opt 
for a penile prosthesis or implant. This requires surgery to replace the corpus cavernosa 
ǁith ŵalleaďle rods or fluid filled Đhaŵďers that ĐaŶ ďe ͚iŶflated/deflated͛ oŶ deŵaŶd. 
Success rates for penile prostheses have been reported as up to 90% (Cummings, 2006). 
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Irrespective of which treatment the man and his partner agree to, some men will benefit 
from relationship or psychosexual counselling. 
 
Psychosexual counselling 
ED can have a profouŶd effeĐt oŶ the ŵaŶ͛s seŶse of self aŶd this ĐaŶ affeĐt his relatioŶship 
with his sexual partner. Although the cause of ED in this group of patients is almost certainly 
associated with surgery, the man has also had to come to terms with a cancer diagnosis, 
which has the potential to alter the way he feels about himself. Some men may prefer to 
explore issues that may arise as a result of either the cancer diagnosis or the side effects of 
the treatment, and therefore psychosexual or relationship counselling may be required.  
 
Conclusion  
ED is common following a radical retropubic prostatectomy (whether nerve-sparing or not). 
Men who had erections that were firm enough for penetration and maintenance of sexual 
activity may find it ͚easier͛ to regain erections post operatively compared with men who had 
ED prior to surgery, although it is difficult to predict how long that recovery will take (if 
ever).  
Men should be encouraged to talk about the potential for erectile dysfunction pre-surgery 
to allow accurate assessment of whether ED is present or not, and to prepare the man for 
coping after surgery. Although options for treatment include PDE5Is, Alprostadil or Vacuum 
Devices alone, there is a growing body of literature that points to a combination approach 
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yielding earlier recovery of erections compared with monotherapy. Therapy selection 
should remain patient driven but based on the best available evidence to support any 
decision.  
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